JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

Search

Eli Lilly and Co.

Suletud

SektorTervishoid

696.49 -1.99

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

694.22

Max

712.89

Põhinäitajad

By Trading Economics

Sissetulek

2.9B

5.7B

Müük

2.8B

16B

P/E

Sektori keskmine

45.864

35.473

Aktsiakasum

6.31

Dividenditootlus

0.8

Kasumimarginaal

36.384

Töötajad

47,000

EBITDA

3.3B

7.5B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+31.86% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.80%

2.38%

Järgmine tulemuste avaldamine

30. okt 2025

Järgmine dividendimakse kuupäev

10. sept 2025

Järgmine aktsia dividendi kuupäev (ex-date)

14. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-62B

629B

Eelmine avamishind

698.48

Eelmine sulgemishind

696.49

Uudiste sentiment

By Acuity

38%

62%

128 / 372 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Eli Lilly and Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. aug 2025, 15:59 UTC

Suurimad hinnamuutused turgudel

Immuneering Shares Climb On Supply Agreement with Eli Lilly

7. aug 2025, 11:36 UTC

Tulu

Eli Lilly Lifts Full-Year Outlook After Revenue Surges on Zepbound, Mounjaro Demand

12. aug 2025, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data -- Barrons.com

8. aug 2025, 19:34 UTC

Market Talk

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8. aug 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7. aug 2025, 16:20 UTC

Tulu

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 4th Update

7. aug 2025, 14:18 UTC

Market Talk
Tulu

Eli Lilly's Orforglipron Results Weigh on Stock -- Market Talk

7. aug 2025, 13:54 UTC

Tulu

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 3rd Update

7. aug 2025, 12:12 UTC

Tulu

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 2nd Update

7. aug 2025, 11:58 UTC

Tulu

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- Update

7. aug 2025, 11:32 UTC

Tulu

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7. aug 2025, 11:03 UTC

Tulu

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7. aug 2025, 10:49 UTC

Tulu

Eli Lilly 2Q Gross Margin 84.3% >LLY

7. aug 2025, 10:48 UTC

Tulu

Eli Lilly 2Q Volume Rose 42%, Realized Prices Fell 6% >LLY

7. aug 2025, 10:47 UTC

Tulu

Eli Lilly Raises 2025 Adjusted Performance Margin View to 43%-44.5% From 41.5%-43.5% >LLY

7. aug 2025, 10:46 UTC

Tulu

Eli Lilly Had Seen 2025 Adjusted EPS $20.78-$22.28 >LLY

7. aug 2025, 10:46 UTC

Tulu

Eli Lilly Had Seen 2025 Revenue $58B-$61B >LLY

7. aug 2025, 10:46 UTC

Tulu

Eli Lilly Raises 2025 View To Rev $60B-$62B >LLY

7. aug 2025, 10:45 UTC

Tulu

Eli Lilly 2Q Net $5.66B >LLY

7. aug 2025, 10:45 UTC

Tulu

Eli Lilly 2Q Rev $15.56B >LLY

7. aug 2025, 10:45 UTC

Tulu

Eli Lilly Sees FY Adj EPS $21.75-Adj EPS $23.00 >LLY

7. aug 2025, 10:41 UTC

Tulu

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6. aug 2025, 20:34 UTC

Tulu

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6. aug 2025, 08:45 UTC

Tulu

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

30. juuli 2025, 10:38 UTC

Market Talk

Novo Nordisk Could Struggle to Regain Investors' Trust -- Market Talk

29. juuli 2025, 17:05 UTC

Tulu

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

29. juuli 2025, 16:55 UTC

Tulu

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

29. juuli 2025, 13:35 UTC

Tulu

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

29. juuli 2025, 11:39 UTC

Tulu

Novo Nordisk Stock Tumbles 20% After Ozempic Maker's Shock Cut to U.S. Outlook -- Barrons.com

25. juuli 2025, 12:49 UTC

Omandamised, ülevõtmised, äriostud

Lilly Completes Acquisition Of Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

Võrdlus sarnastega

Hinnamuutus

Eli Lilly and Co. Prognoos

Hinnasiht

By TipRanks

31.86% tõus

12 kuu keskmine prognoos

Keskmine 938.39 USD  31.86%

Kõrge 1,190 USD

Madal 700 USD

Põhineb 22 Wall Streeti analüütiku instrumendi Eli Lilly and Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

22 ratings

17

Osta

5

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 884.54Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Sentiment

By Acuity

128 / 372 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.